WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

ProKidney (NASDAQ: PROK - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are b

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therap

ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst cons

Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Che

HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy an

ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consens

WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Modera

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst cons

ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the m

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA al

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) wi

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendatio

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consen

WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney

As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly

Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay

Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor w

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consen

https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-

UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilpar

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price

Guggenheim analyst Vamil Divan maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price

U.S. stock futures advanced on Wednesday after ending on a mixed note on Tuesday. Futures of major b